Ko HH, Greanya E, Lee TK, Steinbrecher UP, Erb SR, Yoshida EM

Language: English
References: 21
Page: 376-380
PDF size: 117.64 Kb.

Text Extraction

Background: Calcineurin inhibitors (CNIs) provide effective immunosuppression after orthotopic liver transplantation (OLTx), but the associated nephrotoxicity can cause substantial morbidity and mortality among transplant patients. In this study, we retrospectively investigated the efficacy and safety of mycophenolate mofetil (MMF) in OLTx patients with CNI-induced renal impairment. Patients & Methods: A chart review was undertaken of all liver transplant recipients followed at the Vancouver General Hospital. Twenty-one (12 male) patients were converted to either MMF monotherapy (n = 18) or MMF with corticosteroids (n = 3) for CNI-induced renal dysfunction. Six were excluded because of other factors contributing to renal dysfunction. Mean time from OLTx to conversion was 11.3 years and mean age was 60. Non-parametric Wilcoxon’s signed rank testing was used to determine whether there was a difference between the serum creatinine (SCr) before conversion, and 3 or 6 months after conversion. Results: Median follow-up was 294 days, ranging from 35 to1103 days. The median SCr was significantly reduced from 144 µmol/L before conversion to 129 µmol/L and 139 µ mol/L at 3 and 6 months follow-up (p = 0.001 and 0.008, respectively). MMF was well tolerated. Only one patient (6.7%) had elevated liver enzymes and required addition of sirolimus while two (13.4%) experienced gastrointestinal intolerance. Conclusions: MMF appears to be safe for stable OLTx recipients with CNI-induced nephrotoxicity. Serious side effects were uncommon as only one patient required discontinuation of the medication. However, longer follow-up and larger study populations are needed in the future to better determine its efficacy and safety.

REFERENCES

1. http://www.optn.org/data

2. Gonwa TA, Mai ML, Melton LB, et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation 2001; 72: 1934-1939.

3. Danovitch GM. Immunosuppressant-induced metabolic toxicities. Transplant Rev 2000; 14(2): 65-81.

4. Pawarode A, Fine DM, Thuluvath PJ. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl 2003; 9: 741-747.

5. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a non-renal organ. NEJM 2003; 349: 931-940.

6. Yoshida EM, Marotta PJ, Grieg PD, et al. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial. Liver Transpl 2005; 9: 1064-72.

7. Sandborn WJ, Hay JH, Porayko MK, et al. Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection. Hepatology 1994; 4: 925-32.

8. Chan CY, Dasgupta K, Baker AL, et al. Cyclosporin A: drug discontinuation for the management of long-term toxicity after liver transplantation. Hepatology 1996; 24: 1085-9.

9. Lipsky JL. Mycophenolate mofetil. Lancet 1996; 348; 1357.

10. Finzi D, Sicilian RF. Taking aim at HIV replication. Nat Med 2000; 6: 735-6.

11. Schlitt HJ, Barkmann A, Boker KK, et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomized controlled study. Lancet 2001; 357: 587-91.

12. Herrero JI, Guiroga J, Sangro B, et al. Conversion from cyclosporine A to mycophenolate mofetil in liver transplant recipients with renal function impairment. Transplantation 1998; 65: S51.

13. Jain A, Fung J, Hamad I, et al. Use of mycophenolate mofetil for tacrolimus related chronic nephrotoxicity in liver transplant recipients. Hepatology 1997; 26 (Suppl.): 235A.

14. Koch RO, Graziadei IW, Schutz F, et al. Long-term efficacy and safety of mycophenolate mofetil in liver transplant recipients with calcineurin inhibitor-induced renal dysfunction. Transpl Int 2004; 17(9): 518-24.

15. Morneo JM, Cuervas-Mons V, Rubio E, et al. Mycophenolate mofetil can be used as monotherapy late alter liver transplantation. Am J Transplant 2004; 4: 1650-5.

16. Pierini A, Mirabella S, Brunati A, et al. Mycophenolate mofetil monotherapy in liver transplantation. Transplant Proc 2005; 37(6): 2614-5.

17. Beckebaum S, Cicinnati VR, Klein CG, et al. Impact of combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy on renal function, cardiovascular risk factors, and graft function in liver transplant patients: preliminary results of an open prospective study. Transplant Proc 2004; 36(9): 2671-4.

18. Bilbao I, Castells L, Rojas J, et al. Immunosuppression based on mycophenolate mofetil in stable liver transplanted patients. Int Immunopharmacology 2006; 6: 1977-83.

19. Stewart SF, Hudson M, Talbot D, et al. Mycophenolate mofetil monotherapy in liver transplantation. Lancet 2001; 357 (9256): 609-10.

20. Fairbanks KD, Thuluvath PJ. Mycophenolate mofetil monotherapy in liver transplant recipients: a single center experience. Liver Transplant 2004; 10(9): 1189-94.

21. Raimondo ML, Dagher L, Papatheodoridis GV, et al. Long term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Transplantation 2003; 75: 186-90.